Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07130903) titled 'Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer' on Aug. 12.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Barbara Ann Karmanos Cancer Institute
Condition:
Metastatic Colorectal Adenocarcinoma
Intervention:
Drug: Fruquintinib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 2025
Target Sample Size: 102
To know more, visit https://clinicaltria...